跳至主要内容

CRO employee turnover rate falls as industry matures, survey finds


Over the last three years US turnover in clinical monitoring has dropped from 29.4% to 16.4% and globally overall company turnover has dropped from 27.2% to 14.2% on average, according to the 16th annual CRO Industry Global Compensation and Turnover Survey.

The survey from HR+Survey Solutions found that turnover globally was the highest in Switzerland, New Zealand and Hong Kong.
Study author Judy Canavan told Outsourcing-Pharma.com, “The CRO industry is a niche industry so it is easy for a couple of companies to drive high turnover numbers in a specific country. The industry is expanding rapidly... This growth creates a demand for talent which drives turnover.”
She noted that the falling turnover rates in the past couple of years may be a sign that the industry is maturing. The relatively high turnover rate that remains, she added, seems to be the product of a number of factors, including:
  • Home-based positions that create two issues (1) changing jobs is as simple as getting a new computer, VPN and password (2) it is harder to create a cohesive team when employees do not see each other every day;
  • Travel – many of these positions require extensive travel, employees may find a job that has less travel or travel to a more desirable location;
  • The demands placed in some of these positions are high – in addition to extensive travel there can be tight deadlines, tight budgets and high performance expectations; and
  • CV building – if there is an opportunity to enhance one’s resume, then it may be worth changing jobs for future career growth. 
In terms of retaining talent, Canavan told us that annual corporate bonuses are probably not “the answer for all positions,” and there “needs to be more customization of incentive comp and rewards to meet the needs of individual areas of the company.”
Smaller CROs may have to do more to incentivize employees to stay at the companies, the survey said. It also found that non-management employees of large and small companies are paid comparable salaries, though smaller companies are less likely to pay annual incentives than larger companies.
Nearly 88 percent of director level positions at the larger US CROs received annual incentives versus 65 percent at smaller companies, the survey found.
The CRO with 200 employees is competing for talent against CROs with 10,000 employees. Smaller companies should be using variable pay to help them compete against larger companies for top talent while controlling fixed costs,” said Canavan.
Other findings from the survey include:
  • Average salary levels in the survey only increased by 1% for non-management positions;
  • CRO pay for executives is more heavily weighted toward salaries than in general industry; and
  • On average, the bonus for smaller companies is almost 25 percent less than that for larger companies; however, the size of the awards for smaller companies that pay bonuses tends to be similar to that of the larger companies.

评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...